Summit Therapeutics plc (Nasdaq: SMMT) announces that it has enrolled the first patient in PhaseOut DMD, a Phase 2 proof ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE